TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07217301: A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Sponsor: Takeda · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 1200 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$16,007,376

Rescue Site Savings

+$10,562,244

Unlock Full NCT07217301 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07217301 Rescue Dossier →